Nobligan Retard (Tramadol Hydrochloride)

Tramadol, the active ingredient in Nobligan Retard, is an opioid analgesic presented as an oral dosage form for oral use. It is indicated for the management of moderate to severe pain in adult patients. The formulation is designed for controlled release, delivering sustained analgesia over several hours.

GNH USA supplies Nobligan Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our global distribution network ensures timely delivery and compliance with local regulatory requirements, and dedicated technical support.

Tramadol is used to alleviate pain by acting on the central nervous system, and it is prescribed for several clinical situations.

- Acute postoperative pain: provides effective analgesia following surgical procedures, reducing the need for additional opioid rescue medication. - Chronic musculoskeletal pain: helps manage persistent pain associated with conditions such as osteoarthritis or low back pain. - Cancer-related pain: used as part of a multimodal regimen for moderate to severe pain in oncology patients. - Severe trauma pain: offers relief for intense pain resulting from major injuries or fractures.

Tramadol may cause a range of adverse reactions, varying from mild to serious, that should be monitored during therapy.

Common Side Effects: - Nausea: mild to moderate feeling of sickness that may occur after dosing. - Dizziness: transient light‑headedness or vertigo, especially when standing quickly. - Constipation: reduced bowel movements, often requiring dietary adjustments. - Somnolence: increased sleepiness or fatigue during daily activities.

Serious or Rare Side Effects: - Seizures: risk of convulsions, particularly at high doses or with interacting drugs. - Respiratory depression: slowed breathing that can be life‑threatening, especially in opioid‑naïve patients. - Serotonin syndrome: symptoms such as agitation, hyperthermia, and muscle rigidity when combined with serotonergic agents.

When prescribing Tramadol, clinicians should evaluate patient history and follow safety measures to minimise risks.

- Assess pain severity: confirm that the pain level justifies opioid therapy. - Review seizure history: avoid use in patients with uncontrolled epilepsy or prior seizures. - Evaluate respiratory status: caution in individuals with asthma, COPD, or sleep‑apnea. - Check for serotonergic drugs: monitor for interactions that could precipitate serotonin syndrome. - Monitor for dependence: assess for signs of misuse or addiction during treatment. - Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Tramadol interacts with several medication classes; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid): - MAO inhibitors: concurrent use can cause hypertensive crisis or serotonin syndrome. - SSRIs, SNRIs, or other serotonergic agents: increase risk of serotonin syndrome. - CNS depressants (benzodiazepines, barbiturates): may produce additive sedation and respiratory depression. - Anticonvulsants (e.g., carbamazepine): may reduce tramadol plasma levels, decreasing analgesic effect.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypotensive effects, requiring blood pressure monitoring. - Anticoagulants (warfarin, DOACs): possible increase in bleeding risk, necessitating coagulation checks. - Alcohol: can amplify central nervous system depression and impair coordination.